# US 2026/0085062 A1 · Novel compounds as ck2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085062 A1
- Document ID: US20260085062A1
- Status: Published application
- Kind: A1
- Application number: 19/109,724
- Filed: 2023-09-08
- Published: 2026-03-26
- Earliest claimed: 2022-09-08
- Assignees: Cambridge Enterprise Limited
- Applicants: Cambridge Enterprise Limited
- Inventors: Paul Glossop; Marko Juhana Hyvonen; Paul Brear; David Robert Spring
- Web page: https://patentgrep.com/patent/US20260085062A1

## CPC

- C07D 403/14: containing three or more hetero rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.

## Claims

### Claim 1

A compound of formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof:
wherein:
L is linker that separates RL from RR by 7 to 13 bond lengths;
RL is selected from one of formulae Ic, Id, Ie, If, Ig, Ih, Ii, Ij or Ik shown below:
wherein:
Ra and Re are each independently selected from hydrogen, methyl or halo;
Rb and Rd are each independently selected from hydrogen, halo, cyano, (1-4C)alkyl, (3-6C)cycloalkyl,
—[CH2]0-3-(1-4C)alkoxy,
—[CH2]0-3—C(O)NH2,
—[CH2]0-3—C(O)NH(1-4C)alkyl,
—[CH2]0-3—C(O)N[(1-4C)alkyl]2,
—[CH2]0-3—NH2,
—[CH2]0-3—NH(1-4C)alkyl,
—[CH2]0-3—N[(1-4C)alkyl]2,
—[CH2]0-3—S(O)q-(1-4C)alkyl (wherein q is 0, 1 or 2),
—[CH2]0-3—C(O)(1-4C)alkyl,
—[CH2]0-3—C(O)OH,
—[CH2]0-3—C(O)O-(1-4C)alkyl,
—[CH2]0-3—N(Rf)C(O)-(1-4C)alkyl (wherein Rf is hydrogen or methyl),
—[CH2]0-3—S(O)2NH(1-4C)alkyl,
—[CH2]0-3—S(O)2N[(1-4C)alkyl]2,
—[CH2]0-3—N(R9)SO2-(1-4C)alkyl (wherein R9 is hydrogen or methyl),
a group of the formula:
wherein Y1 is absent, —O—, —NH—, —NMe-, —S—, —S(O)— or —S(O)2—; and
Z1 is (3-6C)cycloalkyl, phenyl, a 4- to 6-membered heterocyclyl or 5 or 6-membered heteroaryl;
and wherein:
any alkyl, alkoxy, cycloalkyl or —[CH2]— moiety within a Rb and Rd substituent group is optionally substituted by one or more substituents selected from halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, or (3-4C)cycloalkoxy; and
Z1 is optionally substituted by one or more substituents selected from: halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkoxy, —C(O)NH(1-2C)alkyl, —C(O)N[(1-2C)alkyl]2, —NH(1-2C)alkyl, -N[(1-2C)alkyl]2, —S(O)q-(1-2C)alkyl (wherein q is 0, 1 or 2), —C(O)(1-2C)alkyl, —C(O)O-(1-2C)alkyl, —N(Rf)C(O)-(1-2C)alkyl, —S(O)2NH(1-2C)alkyl, —S(O)2N[(1-2C)alkyl]2, or —NHSO2-(1-2C)alkyl, and wherein any (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl or (3-4C)cycloalkoxy group is optionally substituted by one or more substituents selected from halo, cyano, hydroxy, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)alkoxy-(1-2C)alkyl;
Rc is selected from hydrogen, halo, cyano, —C(O)NH2, (1-4C)alkyl, (3-6C)cycloalkyl
—[CH2]0-3-(1-4C)alkoxy,
—[CH2]0-3-(3-6C)cycloalkoxy,
—[CH2]0-3—C(O)NH2,
—[CH2]0-3—C(O)NH(1-4C)alkyl,
—[CH2]0-3—C(O)N[(1-4C)alkyl]2,
—[CH2]0-3—NH2,
—[CH2]0-3—NH(1-4C)alkyl,
—[CH2]0-3—N[(1-4C)alkyl]2,
—[CH2]0-3—S(O)q-(1-4C)alkyl (wherein q is 0, 1 or 2),
—[CH2]0-3—C(O)(1-4C)alkyl,
—[CH2]0-3—C(O)OH,
—[CH2]0-3—C(O)O-(1-4C)alkyl,
—[CH2]0-3—N(Rb)C(O)-(1-4C)alkyl (wherein Rh is hydrogen or methyl),
—[CH2]0-3—S(O)2NH(1-4C)alkyl,
—[CH2]0-3—S(O)2N[(1-4C)alkyl]2,
—[CH2]0-3—N(Ri)SO2-(1-4C)alkyl (wherein Ri is hydrogen or methyl),
a group of the formula:
wherein Y2 is absent, —O—, —NH—, —NMe-, —S—, —S(O)— or —S(O)2—; and
Z2 is (3-6C)cycloalkyl, phenyl, a 4- to 6-membered heterocyclyl or 5 or 6-membered heteroaryl;
and wherein:
any alkyl, alkoxy, cycloalkyl or —[CH2]— moiety within a Rc substituent group is optionally substituted by one or more substituents selected from halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, or (3-4C)cycloalkoxy; and
Z2 is optionally substituted by one or more substituents selected from: halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkoxy, —C(O)NH(1-2C)alkyl, —C(O)N[(1-2C)alkyl]2, —NH(1-2C)alkyl, -N[(1-2C)alkyl]2, —S(O)q-(1-2C)alkyl (wherein q is 0, 1 or 2), —C(O)(1-2C)alkyl, —C(O)O-(1-2C)alkyl, —N(Rf)C(O)-(1-2C)alkyl, —S(O)2NH(1-2C)alkyl, —S(O)2N[(1-2C)alkyl]2, or —NHSO2-(1-2C)alkyl, and wherein any (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl or (3-4C)cycloalkoxy group is optionally substituted by one or more substituents selected from halo, cyano, hydroxy, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)alkoxy-(1-2C)alkyl;
R100 is (1-2C)alkyl optionally substituted by hydroxy or halo;
R100a is selected from hydrogen or methyl;
or R100 and R100a are linked to form a cyclopropyl or cyclobutyl ring;
R101 is hydrogen or (1-2C)alkyl optionally substituted by hydroxy or halo;
R101a is selected from hydrogen or methyl;
or R101 and R101a are linked to form a cyclopropyl or cyclobutyl ring;
integer a is 0, 1 or 2;
Q1 is selected from —NR102—, —O—, —S— or —CH—;
R102 is hydrogen or (1-2C)alkyl;
represents a single or double bond;
Q2 is N or CRa;
Q3 is N or CRb;
Q4 is N or CRc;
Q5 is N or CRd;
Q6 is N or CRe;
Ra, Rb, Rc, Rd and Re are each as defined above;
with the proviso that one to three of Q2, Q3, Q4, Q5 or Q6 is/are N;
Q7 is N or CRf;
Q8 is N or CRf;
Q9 is N or CRf;
Q10 is N or CRf;
with the proviso that one or two of Q7, Q8, Q9 or Q10 is/are N;
each Rf present is independently selected from hydrogen, methyl or halo;
Ring A is a five-membered heteroaryl ring optionally substituted by one Rb and/or one or two Rc substituents;
RR is selected from one of formulae Im, In or Io shown below:
wherein:
denotes the point of attachment;
A1 and A2 are both CH; or one of A1 and A2 is N and the other is CH;
R1 is a 5- or 6-membered heteroaryl ring which is optionally substituted on any available carbon atom by one or more R1A substituent groups and on any available nitrogen atom by one or more R1B substituent groups; and wherein:
each R1A group present is selected from hydroxy, cyano, amino, halo, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkoxy, —C(O)NH(1-2C)alkyl, —C(O)N[(1-2C)alkyl]2, —NH(1-2C)alkyl, —N[(1-2C)alkyl]2, —S(O)q-(1-2C)alkyl (wherein q is 0, 1 or 2), —C(O)(1-2C)alkyl, —C(O)O-(1-2C)alkyl, —N(Rf)C(O)-(1-2C)alkyl (wherein Rf is hydrogen or methyl), —S(O)2NH(1-2C)alkyl, —S(O)2N[(1-2C)alkyl]2, or —NHSO2-(1-2C)alkyl; and wherein any (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl or (3-4C)cycloalkoxy group is optionally substituted by one or more substituents selected from halo, cyano, hydroxy, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)alkoxy-(1-2C)alkyl];
and R1B is (1-2C)alkyl or (3-4C)cycloalkyl;
A3 is selected from CH, CR3 or N;
A4 is selected from CH, CR4 or N;
A5 and A6 are both C, or one of A5 and A6 is N and the other is C;
A7 is selected from CH, CR7 or N;
R2 is selected from:
(iii) a group R1 defined above;
(iv) hydrogen, halo, cyano, (1-4C)alkyl, (1-4C)cyanoalkyl, (1-4C)hydroxyalkyl, (1-4C)haloalkyl, (1-4C)aminoalkyl,
—[CH2]0-3-(1-4C)alkoxy,
—[CH2]0-3—C(O)NH2,
—[CH2]0-3—C(O)NH(1-4C)alkyl,
—[CH2]0-3—C(O)N[(1-4C)alkyl]2,
—[CH2]0-3—NH(1-4C)alkyl,
—[CH2]0-3—N[(1-4C)alkyl]2,
—[CH2]0-3—S(O)q-(1-4C)alkyl (wherein q is 0, 1 or 2),
—[CH2]0-3—C(O)(1-4C)alkyl,
—[CH2]0-3—C(O)OH,
—[CH2]0-3—C(O)O-(1-4C)alkyl,
—[CH2]0-3—N(R2a)C(O)-(1-4C)alkyl (wherein R2a is hydrogen or methyl),
—[CH2]0-3—S(O)2NH(1-4C)alkyl,
—[CH2]0-3—S(O)2N[(1-4C)alkyl]2,
—[CH2]0-3—N(R2b)SO2-(1-4C)alkyl (wherein R2b is hydrogen or methyl),
a 4- to 7-membered heterocyclyl,
(3-6C)cycloalkyl,
(3-6C)cycloalkyl(1-2C)alkyl,
phenyl, or
phenyl(1-2C)alkyl;
and wherein any cycloalkyl, heterocyclyl or phenyl group present is optionally substituted by one or more hydroxy, cyano, amino, halo, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl, —C(O)NH(1-2C)alkyl, —C(O)N[(1-2C)alkyl]2, —NH(1-2C)alkyl, —N[(1-2C)alkyl]2, —S(O)q-(1-2C)alkyl (wherein q is 0, 1 or 2), —C(O)(1-2C)alkyl, —C(O)O-(1-2C)alkyl, —N(Rf)C(O)-(1-2C)alkyl (wherein Rf is hydrogen or methyl), —S(O)2NH(1-2C)alkyl, —S(O)2N[(1-2C)alkyl]2, or —NHSO2-(1-2C)alkyl;
R3 is selected from fluoro, chloro, methyl, methoxy or cyano;
R4 is selected from fluoro, chloro, methyl, methoxy or cyano;
R7 is selected from methyl, —NH(1-2C)alkyl or —NH(3-4C)cycloalkyl;
and wherein R2 is not a group R1 when A3, A4 and A7 are all CH and A5 and A6 are C;
A8 is selected from CH, CR8, O, S, NH or N;
A9 is selected from CH, CR9, O, S, NH or N;
A10 is selected from CH, CR10, O, S, NH or N;
R8, R9 and R10 are selected from methyl, amino, —NH(1-2C)alkyl or —NH(3-4C)cycloalkyl;
and wherein:
(i) only one of A8, A8 and A10 can be NH;
(ii) one to four of A5, A8, A9 and A10 or A6, A8, A9 and A10 can be N
(iii) only one of A8, A9 or A10 can be O or S;
(iv) when one of A8, A8 or A10 are O or S, A5 and/or A6 cannot be N.

### Claim 2 (depends on 1)

A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is linker that separates RL from RR by 8 to 12 bond lengths, 9 to 11 bond lengths, or 10 bond lengths.

### Claim 3 (depends on 1, 2)

A compound according to any one of claims 1 or 2, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
(ii) a group of the formula:
wherein:
XA is selected from: —O—, —S—, —SO—, —SO2—, —N(Rxa)—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(Rxa)—, —N(Rxa)C(O)—, —N(Rxa1)C(O)N(Rxa)—, —S(O)2N(Rxa)— or —N(Rxa)SO2—, wherein Rxa and Rxa1 are selected from hydrogen or methyl;
LA is a (1-6C)alkylene optionally substituted by one or more RLA substituent groups, or a -[(0-3C)alkylene-(3-6C)cycloalkylene-(0-3C)alkylene]-group optionally substituted by one or more RLA substituent groups;
each RLA group present is selected from hydroxy, halo, (1-2C)alkyl, (1-2C)hydroxyalkyl or (1-2C)haloalkyl;
XB is selected from: —O—, —S—, —SO—, —SO2—, —N(Rxb)—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(Rxb)—, —N(Rxb)C(O)—, —N(Rxb)C(O)N(Rxb)—, —S(O)2N(Rxb)— or —N(Rxb)SO2—, wherein Rxb and Rxb1 are selected from hydrogen or methyl;
LB is a (1-6C)alkylene optionally substituted by one or more RLB substituent groups, or a -[(0-3C)alkylene-(3-6C)cycloalkylene-(0-3C)alkylene]-group optionally substituted by one or more RLB substituent groups;
each RLB group present is selected from hydroxy, halo, (1-2C)alkyl, (1-2C)hydroxyalkyl or (1-2C)haloalkyl;
Xc is selected from: —O—, —S—, —SO—, —SO2—, —N(Rxc)—, —C(O)—, —C(O)O—, —OC(O)—, —C(O)N(Rxc)—, —N(Rxc1)C(O)—, —N(Rxc1)C(O)N(Rxc)—, —S(O)2N(Rxc)— or —N(Rxc)SO2—, wherein Rxc and Rxc1 are selected from hydrogen or methyl;
(ii) a group of the formula:
wherein:
XA, LA, XB, LB and XC are as defined above;
QA is selected from a 5 or 6-membered heteroaryl ring, a 9 or 10-membered bicyclic heteroaryl ring, (3-6C)cycloalkyl, a phenyl, or a 4 to 6 membered heterocyclic ring;
(iii) a group of the formula:
wherein:
XA and XB are each as defined above;
integer m is 1 or 2.

### Claim 4

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
(i) a group of the formula:
wherein:
XA is selected from: —O—, —SO2—, —N(Rxa)—, —C(O)—, —C(O)N(Rxa)—, —N(Rxa)C(O)—, —S(O)2N(Rxa)— or —N(Rxa)SO2—, wherein Rxa is selected from hydrogen or methyl;
LA is a (1-5C)alkylene optionally substituted by one or more RLA substituent groups, or a -[(0-2C)alkylene-(3-6C)cycloalkylene-(0-2C)alkylene]-group optionally substituted by one or more RLA substituent groups;
each RLA group present is selected from (1-2C)alkyl, (1-2C)hydroxyalkyl or (1-2C)haloalkyl;
XB is selected from: —O—, —SO2—, —N(Rxb)—, —C(O)—, —C(O)N(Rxb)—, —N(Rxb1)C(O)—, —S(O)2N(Rxb)— or —N(Rxb)SO2—, wherein Rxb and Rxb1 are selected from hydrogen or methyl;
LB is a (1-4C)alkylene optionally substituted by one or more RLB substituent groups, or a -[(0-2C)alkylene-(3-6C)cycloalkylene-(0-2C)alkylene]-group optionally substituted by one or more RLB substituent groups;
each RLB group present is selected from (1-2C)alkyl, (1-2C)hydroxyalkyl or (1-2C)haloalkyl;
Xc is selected from: —O—, —SO2—, —N(Rxc)—, —C(O)—, —C(O)N(Rxc)—, —N(Rxc1)C(O)—, —S(O)2N(Rxc)— or —N(Rxc)SO2—, wherein Rxc and Rxc1 are selected from hydrogen or methyl;
(ii) a group of the formula:
wherein:
XA, LA, XB, LB and XC are as defined above;
QA is selected from a 5 or 6-membered heteroaryl ring, or a 4 to 6 membered heterocyclic ring;
(iii) a group of the formula:
wherein:
XA and XB are each as defined above:
integer m is 1.

### Claim 5

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
(i) a group of the formula:
wherein:
XA is selected from: —O—, —N(Rxa)—, —C(O)N(Rxa)—, or —N(Rxa)C(O)—, wherein Rxa is selected from hydrogen or methyl;
LA is a (2-5C)alkylene optionally substituted by one or more RLA substituent groups, or a -[(4-6C)cycloalkylene-(0-1C)alkylene]-group, each RLA group present is (1-2C)alkyl;
XB is selected from: —O—, —N(Rxb)—, —C(O)N(Rxb)—, or —N(Rxb1)C(O)—, wherein Rxb and Rxb1 are selected from hydrogen or methyl;
LB is a (1-4C)alkylene optionally substituted by one or more RLB substituent groups,
each RLB group present is (1-2C)alkyl;
Xc is selected from: —O—, —N(Rxc)—, —C(O)N(Rxc)— or —N(Rxc1)C(O)—, wherein Rxc and Rxc1 are selected from hydrogen or methyl;
(ii) a group of the formula:
wherein:
XA, LA, XB, LB and XC are as defined above;
QA is selected from a 5 or 6-membered heteroaryl ring, or a 4 to 6 membered heterocyclic ring.

### Claim 6

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:
(i) a group of the formula:
wherein:
XA is selected from: —N(H)—, or —N(Me)-;
LA is a (2-4C)alkylene optionally substituted by a methyl group, or LA is a -[cyclobutylene-(0-1C)alkylene]-group;
XB is selected from: —O—, —N(H)—, —N(Me)-, —C(O)N(H)—, or —C(O)N(Me)-;
LB is a (1-4C)alkylene;
Xc is selected from: —O—, —N(H)—, —N(Me)-, —C(O)N(H)— or —C(O)N(Me)-;
(ii) a group of the formula:
wherein:
XA, LA, XB, LB and XC are as defined above;
QA is selected from an oxazole group, triazole group or a azetidine group.

### Claim 7

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein L is a linker selected from:

### Claim 8

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein RL is selected from one of formulae Ic, Ie or If shown below:
wherein:
denotes the point of attachment;

### Claim 9

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein RL is selected from one of formulae shown below:
wherein:
denotes the point of attachment.

### Claim 10

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Ra and Re are both hydrogen.

### Claim 11

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Rb and Rd are each independently selected from hydrogen, halo, cyano, (1-4C)alkyl, (3-6C)cycloalkyl,
—[CH2]0-1-(1-4C)alkoxy,
—[CH2]0-1—C(O)NH2,
—[CH2]0-1—C(O)NH(1-2C)alkyl,
—[CH2]0-1—C(O)(1-2C)alkyl,
—[CH2]0-1—C(O)OH,
a group of the formula:
wherein Y1 is absent, —O—, —NH—, —NMe-, —S—, —S(O)— or —S(O)2—; and
Z1 is (3-6C)cycloalkyl, phenyl, a 4- to 6-membered heterocyclyl or 5 or 6-membered heteroaryl;
and wherein:
any alkyl, alkoxy, cycloalkyl or —[CH2]— moiety within a Rb and Rd substituent group is optionally substituted by one or more substituents selected from halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, or (3-4C)cycloalkoxy; and
Z1 is optionally substituted by one or more substituents selected from: halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkoxy, —C(O)NH(1-2C)alkyl, —C(O)N[(1-2C)alkyl]2, —NH(1-2C)alkyl, —N[(1-2C)alkyl]2, —C(O)(1-2C)alkyl, —C(O)O-(1-2C)alkyl or —N(Rf)C(O)—(1-2C)alkyl, and wherein any (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl or (3-4C)cycloalkoxy group is optionally substituted by one or more substituents selected from halo, cyano, hydroxy, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)alkoxy-(1-2C)alkyl.

### Claim 12

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein one of Rb and Rd is hydrogen or halogen and the other is selected from hydrogen, fluoro, chloro cyano, methyl, ethyl, methoxy, ethoxy, —C(O)NH2, —CH2-oxazole, —CH2OH, —CH2CN, —CH2CH2OH, —CF3, —OCF3, —O—CH2CH2OH or —CH2—C(O)NH2.

### Claim 13

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Rc is selected from hydrogen, halo, cyano, —C(O)NH2, (1-4C)alkyl, (3-6C)cycloalkyl, -(1-4C)alkoxy,
a group of the formula:
wherein Y2 is absent, —O—, —NH— or —NMe-; and
Z2 is (3-6C)cycloalkyl, phenyl, a 4- to 6-membered heterocyclyl or 5 or 6-membered heteroaryl;
and wherein:
any alkyl, alkoxy, cycloalkyl or —[CH2]— moiety within a Rc substituent group is optionally substituted by one or more substituents selected from halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, or (3-4C)cycloalkoxy; and
Z2 is optionally substituted by one or more substituents selected from: halo, hydroxy, cyano, amino, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkoxy, —C(O)NH(1-2C)alkyl, —C(O)N[(1-2C)alkyl]2, —NH(1-2C)alkyl, —N[(1-2C)alkyl]2, —C(O)(1-2C)alkyl or —C(O)O-(1-2C)alkyl, and wherein any (1-2C)alkoxy, (1-2C)alkyl, (3-4C)cycloalkyl or (3-4C)cycloalkoxy group is optionally substituted by one or more substituents selected from halo, cyano, hydroxy, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)alkoxy-(1-2C)alkyl.

### Claim 14

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Rc is selected from hydrogen, —CF3, —OCF3, cyclopropyl, phenyl, —O-cyclobutyl or -phenyl-CH2—OH;

### Claim 15

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein RR is selected from one of formulae Im or In shown below:
wherein:
denotes the point of attachment;

### Claim 16

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is a 5- or 6-membered heteroaryl ring comprising one, two, three or four heteroatoms selected from N, O or S which is optionally substituted on any available carbon atom by one or more R1A substituent groups and on any available nitrogen atom by one or more R1B substituent groups;

### Claim 17

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is selected from:
wherein R1A is as defined herein;

### Claim 18

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein each R1A group present is selected from hydroxy, cyano, amino, chloro, fluoro, —C(O)OH, —C(O)NH2, (1-2C)alkoxy, (1-2C)alkyl; and wherein any (1-2C)alkoxy, (1-2C)alkyl group is optionally substituted by one or more substituents selected from halo, cyano, hydroxy, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)alkoxy-(1-2C)alkyl.

### Claim 19

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein each R1B group is methyl.

### Claim 20

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from:
(i) a group R1 defined above;
(ii) hydrogen, halo, cyano, (1-2C)alkyl, (1-2C)cyanoalkyl, (1-2C)hydroxyalkyl, (1-2C)haloalkyl, (1-2C)aminoalkyl,
—[CH2]0-1-(1-2C)alkoxy,
—[CH2]0-1—C(O)NH2,
—[CH2]0-1—C(O)NH(1-2C)alkyl,
—[CH2]0-1—C(O)N[(1-2C)alkyl]2,
—[CH2]0-1—C(O)(1-2C)alkyl,
—[CH2]0-2—C(O)OH,
—[CH2]0-1—C(O)O-(1-2C)alkyl,
—[CH2]0-1—N(H)C(O)—(1-2C)alkyl,
a 4- to 6-membered heterocyclyl,
(4-6C)cycloalkyl,
(4-6C)cycloalkyl(1-2C)alkyl,
phenyl, or
phenyl(1-2C)alkyl;
and wherein any cycloalkyl, heterocyclyl or phenyl group present is optionally substituted by one or more hydroxy, cyano, amino, halo, —C(O)OH, —C(O)NH2, methoxy, methyl, —C(O)NH(Me), —C(O)N(Me)2, —NH(Me), —N(Me)2, —S(O)q-(Me) (wherein q is 0, 1 or 2), —C(O)(Me), —C(O)O-(Me), —N(H)C(O)-(Me), —S(O)2NH(Me), —S(O)2N(Me)2, or —NHSO2-(Me).

### Claim 21

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from:
(i) a group R1 defined above;
(ii) hydrogen, cyano, —C(O)NH2, —C(O)N(Me)2, CH2CH2—C(O)OH, —C(O)OH, -morpholino, -oxetane, -tetrahydrofuran or -tetrahydropyran.

### Claim 22

A compound according to any one of the preceding claims, or a salt, hydrate or solvate thereof, wherein the compound is selected from any one of the following:
3-(((2-Chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(pyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
4-((3-(3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamido)propyl)amino)-1H-indazole-6-carboxamide;
N-(3-((6-(1H-pyrazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
N-(3-((6-(1H-1,2,4-triazol-1-yl)-1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
3-((3-Chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(pyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(pyridazin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(3-cyano-1H-pyrazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(pyridin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(2-methyl-1H-imidazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-cyano-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-3-(3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamido)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chlorobenzyl)amino)propanamide;
N-(2-(4-(2-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)ethyl)-1H-1,2,3-triazol-1-yl)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-2-(2-(2-((3-chloro-4-(trifluoromethoxy)benzyl)amino)ethyl)oxazol-5-yl)acetamide;
N-(2-(5-(2-((3-chloro-4-(trifluoromethoxy)benzyl)amino)ethyl)-4H-1,2,4-triazol-3-yl)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-2-((4-((3-chloro-4-(trifluoromethoxy)benzyl)amino)butyl)amino)acetamide;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-3-(3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamido)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)oxy)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-methylpropanamide;
3-(((2-Chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(2-methylpyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-Chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(2-methoxypyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(2-(4-(((6-chloro-1H-benzo[d]imidazol-2-yl)methyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N1-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)ethyl)-N4-(3-chloro-4-(trifluoromethoxy)benzyl)butane-1,4-diamine;
N-(3-((6-(2H-1,2,3-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(pyridin-3-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(3-methyl-1H-pyrazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(isoxazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(4-methyl-1H-imidazol-1-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
4-(4-((3-(3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamido)propyl)amino)-1H-indazol-6-yl)pyridine 1-oxide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(2-oxo-1,2-dihydropyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((6-(1,2,3-thiadiazol-5-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((4-chloro-5-phenyl-1H-pyrazol-3-yl)methyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-(hydroxymethyl)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((6-chloro-1-methyl-1H-indol-2-yl)methyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((6-chloro-1H-indol-2-yl)methyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((1-methyl-5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-cyano-4-cyclobutoxybenzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-(2-hydroxyethyl)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((4-cyclobutoxy-3-(hydroxymethyl)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-(2-hydroxyethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-5-(hydroxymethyl)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-(hydroxymethyl)-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-cyano-4-cyclopropylbenzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-cyano-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-(cyanomethyl)benzyl)amino)propanamide;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-2-(4-((3-chloro-4-(trifluoromethoxy)benzyl)amino)butoxy)acetamide;
6-(4H-1,2,4-triazol-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
N-(2-(4-(((6-chloro-1-methyl-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(2-(4-(((1-methyl-5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(2-(4-(((6-chloro-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(2-(4-(((5-cyclobutoxy-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-((5-cyclobutoxy-1H-indol-2-yl)methyl)-4-(2-((6-(isoxazol-4-yl)-1H-indazol-4-yl)oxy)ethoxy)butan-1-amine;
N-((5-cyclobutoxy-1H-indol-2-yl)methyl)-4-(2-((6-(pyridazin-4-yl)-1H-indazol-4-yl)oxy)ethoxy)butan-1-amine;
4-(2-((6-(pyridazin-4-yl)-1H-indazol-4-yl)oxy)ethoxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
N-(2-(4-(((5-cyclobutoxy-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-6-(pyridazin-4-yl)-1H-indazol-4-amine;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-2′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
4-((3-(3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamido)propyl)amino)-1H-indazole-6-carboxylic acid;
4-((4-((4-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)butyl)amino)butyl)amino)-1H-indazole-6-carboxylic acid;
N-(3-((1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
4-((3-(3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamido)propyl)amino)-N,N-dimethyl-1H-indazole-6-carboxamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(hydroxymethyl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(2-(2-(2-((3-chloro-4-(trifluoromethoxy)benzyl)amino)ethyl)oxazol-5-yl)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-2-(5-(2-((3-chloro-4-(trifluoromethoxy)benzyl)amino)ethyl)-4H-1,2,4-triazol-3-yl)acetamide;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-3-((3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propyl)amino)propanamide;
N1-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)oxy)propyl)-N3-(3-chloro-4-(trifluoromethoxy)benzyl)propane-1,3-diamine;
N-(2-(4-(((6-chloro-1-methyl-1H-benzo[d]imidazol-2-yl)methyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
3-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)oxy)propoxy)-N-(3-chloro-4-(trifluoromethoxy)benzyl)propan-1-amine;
N-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)-3-(3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propoxy)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(3-methyl-4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N1-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)ethyl)-N4-(3-chloro-4-(trifluoromethoxy)benzyl)-N1-methylbutane-1,4-diamine;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(pyrimidin-5-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(2-cyanopyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(pyrimidin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(3-methoxy-1H-pyrazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((4-cyclopropyl-3-(hydroxymethyl)benzyl)amino)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-morpholino-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((6-(2H-tetrazol-5-yl)-1H-indazol-4-yl)amino)propyl)-3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(2-methyl-1H-imidazol-1-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(oxetan-3-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(tetrahydrofuran-3-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((5-(4H-1,2,4-triazol-4-yl)-1H-indazol-7-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
methyl 4-((2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)amino)-1H-indazole-6-carboxylate;
4-((2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)amino)-1H-indazole-6-carboxylic acid;
6-(3-methyl-4H-1,2,4-triazol-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
6-(2-methoxypyridin-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
methyl 3-(4-((2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)amino)-1H-indazol-6-yl)propanoate;
3-(4-((2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)amino)-1H-indazol-6-yl)propanoic acid;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(tetrahydro-2H-pyran-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-(((2-chloro-[1,1′-biphenyl]-4-yl)methyl)amino)-N-(3-((6-(4-methyl-1H-imidazol-5-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
6-(3-methoxy-1H-pyrazol-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
6-(pyridazin-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
6-(pyrimidin-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
4-((2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)amino)-1H-indazole-6-carbonitrile;
6-(isoxazol-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-indazol-4-amine;
N-(2-(4-(((5-cyclobutoxy-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-6-(isoxazol-4-yl)-1H-indazol-4-amine;
N-(2-(4-((3-chloro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-amine;
6-(pyridazin-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-benzo[d][1,2,3]triazol-4-amine;
4-(2-((6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)oxy)ethoxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
N-(3-chloro-4-(trifluoromethoxy)benzyl)-4-(2-((6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)oxy)ethoxy)butan-1-amine;
2-(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-fluorophenyl)acetonitrile;
(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethyl)phenyl)methanol;
2-(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethyl)phenyl)acetonitrile;
2-(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-methylphenyl)acetonitrile;
N-(3-chloro-4-(trifluoromethoxy)benzyl)-4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
N-(3-fluoro-4-(trifluoromethoxy)benzyl)-4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
N-((5-cyclobutoxy-1H-indol-2-yl)methyl)-4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
(3-fluoro-5-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)methanol;
(3-chloro-5-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)methanol;
(3-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethyl)phenyl)methanol;
2-(3-fluoro-5-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)acetonitrile;
2-(3-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethyl)phenyl)acetonitrile;
2-(3-methyl-5-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)acetonitrile;
4-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)oxy)ethoxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
4-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)oxy)ethoxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
4-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)oxy)ethoxy)-N-((5-cyclobutoxy-1H-indol-2-yl)methyl)butan-1-amine;
N-((5-cyclobutoxy-1H-indol-2-yl)methyl)-4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
(3-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethyl)phenyl)methanol;
2-(3-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-methylphenyl)acetonitrile;
2-(3-chloro-5-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)acetonitrile;
4-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)oxy)ethoxy)-N-(3-chloro-4-(trifluoromethoxy)benzyl)butan-1-amine;
4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)-N-((5-cyclobutoxy-1H-indol-2-yl)methyl)butan-1-amine:
(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-fluorophenyl)methanol;
N-(2-(4-((3-chloro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-amine;
N-(2-(4-((3-chloro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-6-(isoxazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-amine;
4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)-N-(3-fluoro-4-(trifluoromethoxy)benzyl)butan-1-amine;
(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-chlorophenyl)methanol;
2-(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-chlorophenyl)acetonitrile;
4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)-N-(3-chloro-4-(trifluoromethoxy)benzyl)butan-1-amine;
2-(3-chloro-5-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)acetonitrile;
2-(3-(((4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
N-(3-fluoro-4-(trifluoromethoxy)benzyl)-4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
(3-chloro-5-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)methanol;
N-(3-chloro-4-(trifluoromethoxy)benzyl)-4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
(3-fluoro-5-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)phenyl)methanol;
4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
4-((1-(6-(pyridazin-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
2-(3-(((4-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)amino)ethoxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
6-(4H-1,2,4-triazol-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-benzo[d][1,2,3]triazol-4-amine:
6-(isoxazol-4-yl)-N-(2-(4-(((5-(trifluoromethyl)-1H-indol-2-yl)methyl)amino)butoxy)ethyl)-1H-benzo[d][1,2,3]triazol-4-amine;
4-(2-((6-(isoxazol-4-yl)-1H-indazol-4-yl)oxy)ethoxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
2-(3-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethyl)phenyl)acetonitrile;
2-(3-(((4-((1-(6-(isoxazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
2-(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
2-(3-(((4-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)oxy)ethoxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
4-((1-(6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)azetidin-3-yl)oxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
N-(3-chloro-4-(trifluoromethoxy)benzyl)-4-((1-(6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)azetidin-3-yl)oxy)butan-1-amine;
2-(3-(((4-((1-(6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)azetidin-3-yl)oxy)-N-((5-(trifluoromethyl)-1H-indol-2-yl)methyl)butan-1-amine;
4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)azetidin-3-yl)oxy)-N-(3-chloro-4-(trifluoromethoxy)benzyl)butan-1-amine;
2-(3-(((4-((1-(6-(4H-1,2,4-triazol-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)azetidin-3-yl)oxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
2-(3-(((4-(2-((6-(pyridazin-4-yl)-1H-benzo[d][1,2,3]triazol-4-yl)oxy)ethoxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(5-cyano-1H-pyrazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((6-(1,3,4-oxadiazol-2-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((7-chloro-6-(pyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(5-methyl-1H-pyrazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-cyano-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((6-(1H-1,2,3-triazol-1-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(3-fluoropyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(3-((1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(oxazol-5-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(3-methylpyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
7-chloro-N-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-6-(pyridin-4-yl)-1H-indazol-4-amine;
4-((2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)amino)-1H-indazole-6-carbonitrile;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(6-oxo-1,6-dihydropyridazin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(3-chloropyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(2-oxo-1,2-dihydropyrimidin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
4-(2-(((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)methyl)amino)ethoxy)-N-(3,5-difluoro-4-(trifluoromethoxy) benzyl)butan-1-amine;
N-(3-(((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)methyl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(1,2,4-oxadiazol-5-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(4H-1,2,4-triazol-3-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(oxazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-7-fluoro-6-(pyridin-4-yl)-1H-indazol-4-amine;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(3-cyano-4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((7-methyl-6-(pyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
N-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-7-methyl-6-(pyridin-4-yl)-1H-indazol-4-amine;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((7-fluoro-6-(pyridin-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((7-chloro-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
7-chloro-N-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(3-((6-(1,2,4-thiadiazol-5-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(2-aminopyridin-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((6-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)amino)propyl)propanamide;
5-chloro-N-(2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-amine;
N-(3-((6-(6-aminopyridazin-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(6-aminopyridazin-4-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N-(3-((6-(1,2,4-oxadiazol-3-yl)-1H-indazol-4-yl)amino)propyl)-3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)propanamide;
N4-(2-(4-((3,5-difluoro-4-(trifluoromethoxy) benzyl)amino) butoxy)ethyl)-N3-methyl-6-(4H-1,2,4-triazol-4-yl)-1H-indazole-3,4-diamine;
3-((3-chloro-4-(trifluoromethoxy)benzyl)amino)-N-(3-((3-(methylamino)-6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)propyl)propanamide;
(S)-(3-(((5-(2-((6-(4H-1,2,4-triazol-4-yl)-1H-indazol-4-yl)amino)ethoxy)pentan-2-yl)amino)methyl)-5-(trifluoromethoxy)phenyl)methanol;
(S)-5-(4-((2-((4-((3-(hydroxymethyl)-5-(trifluoromethoxy)benzyl)amino)pentyl)oxy)ethyl)amino)-1H-indazol-6-yl)pyridazin-3-ol;
(S)-2-(3-(((5-(2-((6-(6-hydroxypyridazin-4-yl)-1H-indazol-4-yl)amino)ethoxy)pentan-2-yl)amino)methyl)-5-(trifluoromethoxy)phenyl)acetonitrile;
(S)-5-(4-((2-((4-((3-(oxazol-5-ylmethyl)-5-(trifluoromethoxy)benzyl)amino)pentyl)oxy)ethyl)amino)-1H-indazol-6-yl)pyridazin-3-ol;
(S)-3-(((5-(2-((6-(isoxazol-4-yl)-1H-indazol-4-yl)amino)ethoxy)pentan-2-yl)amino)methyl)-5-(trifluoromethoxy) benzamide;
4-((2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)amino)-1H-indazole-6-carboxylic acid;
2-(4-((2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)amino)-1H-indazol-6-yl)acetic acid;
5-(4-(2-((3-((3-(2-hydroxyethoxy)-5-(trifluoromethoxy)benzyl)amino)cyclobutyl)methoxy)ethoxy)-1H-indazol-6-yl)pyridazin-3-ol;
5-(4-(2-((3-((3-(hydroxymethyl)-5-(trifluoromethoxy)benzyl)amino)cyclobutyl)methoxy)ethoxy)-1H-indazol-6-yl)pyridazin-3-ol;
3-(4-((2-(4-((3,5-difluoro-4-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)amino)-1H-indazol-6-yl)propanoic acid;
2-(3-(((4-(2-((1H-indazol-4-yl)amino)ethoxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenoxy)ethanol;
(3-(((3-((2-((6-(1,2,3-thiadiazol-5-yl)-1H-indazol-4-yl)amino)ethoxy)methyl)cyclobutyl)amino)methyl)-5-(trifluoromethoxy)phenyl)methanol;
2-(4-((2-(4-((3-(hydroxymethyl)-5-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)amino)-1H-indazol-6-yl)acetonitrile;
2-(3-(((3-((2-((6-(1,2,3-thiadiazol-5-yl)-1H-indazol-4-yl)amino)ethoxy)methyl)cyclobutyl)amino)methyl)-5-(trifluoromethoxy)phenoxy)ethan-1-ol;
2-(4-((2-(4-((3-(hydroxymethyl)-5-(trifluoromethoxy)benzyl)amino)butoxy)ethyl)amino)-1H-indazol-6-yl)-2-methylpropanenitrile;
(S)-(3-(((5-(2-((6-(1,2,3-thiadiazol-5-yl)-1H-indazol-4-yl)amino)ethoxy)pentan-2-yl)amino)methyl)-5-(trifluoromethoxy)phenyl)methanol; and
(R)-(3-(((4-(2-((6-(1,2,3-thiadiazol-5-yl)-1H-indazol-4-yl)amino)propoxy)butyl)amino)methyl)-5-(trifluoromethoxy)phenyl)methanol.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A pharmaceutical composition comprising a compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A compound according to any one of claims 1 to 22, or a pharmaceutically acceptable salt of solvate thereof, or a pharmaceutical composition according to claim 23 for use in:
(i) therapy:
(ii) the treatment of a disease or condition in which CK2α activity is implicated;
(iii) the treatment of a disease or condition associated with aberrant activity of CK2α;
(i) the treatment of proliferative disorders (e.g. cancer or benign neoplasms), viral infections, an inflammatory disease or condition, diabetes, vascular and ischemic disorders, neurodegenerative disorders and/or the regulation of circadian rhythm;
(ii) the treatment of a cancer; and/or
(iii) the treatment of a viral infection.
